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Background and aims: Although it has become clear that aneurysmal and occlusive arterial disease
represent two distinct etiologic entities, it is still unknown whether the two vascular pathologies are
prognostically different. We aim to assess the long-term vital prognosis of patients with abdominal aortic
aneurysmal disease (AAA) or peripheral artery disease (PAD), focusing on possible differences in survival,
prognostic risk proﬁles and causes of death.
Methods: Patients undergoing elective surgery for isolated AAA or PAD between 2003 and 2011 were
retrospectively included. Differences in postoperative survival were determined using Kaplan-Meier and
Cox regression analysis. Prognostic risk proﬁles were also established with Cox regression analysis.
Results: 429 and 338 patients were included in the AAA and PAD groups, respectively. AAA patients were
older (71.7 vs. 63.3 years, p < 0.001), yet overall survival following surgery did not differ (HR: 1.16, 95% CI:
0.87e1.54). Neither was type of vascular disease associated with postoperative cardiovascular nor
cancer-related death. However, in comparison with age- and gender-matched general populations,
cardiovascular mortality was higher in PAD than AAA patients (48.3% vs. 17.3%). Survival of AAA and PAD
patients was negatively affected by age, history of cancer and renal insufﬁciency. Additional de-
terminants in the PAD group were diabetes and ischemic heart disease.
Conclusions: Long-term survival after surgery for PAD and AAA is similar. However, overall life expec-
tancy is signiﬁcantly worse among PAD patients. The contribution of cardiovascular disease towards
mortality in PAD patients warrants more aggressive secondary prevention to reduce cardiovascular
mortality and improve longevity.
© 2016 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Traditionally, dilatation and occlusion were considered to
represent two extremes on the same spectrum of arterial disease.
As such, it was presumed that both entities were the result of
extensive atherosclerosis [1]. This assumptionwas largely based on
the fact that the two vascular diseases share a number of risk fac-
tors, such as smoking, hypertension, and older age [2e6].
However, over the years, disparities in etiologic cardiovascular
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aneurysmal and occlusive disease [7,12e16]. In addition, differences
in cytokine levels, inﬂammation, and enzyme activity were found
in the arterial walls affected by aneurysmal or occlusive disease
[9,17,18]. Also, recent studies show that genetic susceptibility,
rather than environmental risk factors, plays a particularly impor-
tant role in the pathogenesis of aneurysmal disease [19e21].
Although it is becoming clear that aneurysm formation and
atherosclerosis are two separate clinical entities, it remains unclear
whether this also translates into long-term prognostic differences
between the two patient categories. Differences in long-term
outcome, particularly of cardiovascular nature, would warrant
more aggressive secondary prevention regimens for those at the
highest risk.pitalar Lisboa Central August 22, 2016.
pyright ©2016. Elsevier Inc. All rights reserved.
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we aim to determine the long-term vital prognosis for abdominal
aneurysmal and peripheral occlusive disease patients, focusing on
possible differences in survival, risk proﬁles, and causes of death.
2. Patients and methods
Patients undergoing elective surgery for AAA or PAD at the
Erasmus University Medical Centre in Rotterdam between January
2003 and December 2011 were retrospectively identiﬁed using
operation codes and surgical reports. Long-term survival was
assessed from the day of surgery onward. In order to improve ho-
mogeneity in terms of operative stress and severity of disease, all
percutaneous endovascular procedures, i.e. percutaneous endo-
vascular aneurysm repair (EVAR) and percutaneous lower limb PTA
or stenting procedures, were excluded. AAA patients who under-
went prior endovascular or open surgical revascularization for
lower limb ischemia were excluded from this study. PAD patients
who underwent prior treatment of an abdominal or thoracic aortic
aneurysm were also excluded. Treatment indications for AAA and
PAD were both in accordance with the European Society for
Vascular Surgery guidelines [22,23]. Similarly, all vascular surgery
patients were treated in accordance with these guidelines
regarding secondary cardiovascular prevention. As a result, all pa-
tients followed a lifelong regimen of anti-platelets and statins, as
well as anti-hypertensive and anti-diabetes medication on indica-
tion. Baseline characteristics were obtained from hospital charts
and included age, gender, comorbidity, prior vascular interventions,
smoking status (current/former or non-smoker), and body mass
index (BMI). Institutional approval for this study was obtained, and
no informed consent was required according to local directives for
retrospective studies. The study complies with the Helsinki decla-
ration on research ethics.
2.1. Deﬁnitions
Diabetesmellitus was recorded if diabetes wasmentioned in the
medical history or if patients used insulin or oral anti-diabetics.
Hypertension was deﬁned as blood pressure >140/90 mmHg or
use of anti-hypertensive medication. A history of cancer was
deﬁned as past or current malignant neoplastic disease, except for
basal cell carcinoma. Renal insufﬁciency was deﬁned as an esti-
mated glomerular ﬁltration rate (eGFR) < 60 ml/min as calculated
from preoperative serum creatinine levels using the MDRD for-
mula. Smoking status and BMI were derived from the medical re-
cords. Cerebrovascular disease was deﬁned as mentioning of
symptomatic carotid artery disease (i.e., transient ischemic attack
or stroke) and/or a carotid endarterectomy or stenting procedure in
themedical history. Ischemic heart disease was considered if one of
the following was present: reference to previous cardiac ischemic
events in cardiology notes, prior coronary intervention or evidence
of myocardial ischemia in provocative pre-operative tests (dobut-
amine stress echocardiography or myocardial scintigraphy). Prior
vascular interventions were deﬁned as either surgical or percuta-
neous vascular treatment prior to the index operation, not
including coronary revascularization.
2.2. Endpoints
The primary endpoint was overall mortality. Secondary end-
points were cardiovascular and cancer-related death.
2.3. Cause of death
Causes of death were obtained from the Dutch Central Bureau ofDownloaded from ClinicalKey.com at Centro H
For personal use only. No other uses without permissionStatistics (CBS). A database consisting of medical data on the study
participants was anonymized by authorized data managers
employed by CBS. This data set was subsequently imported and
linked to the Dutch death registry, which is maintained by the CBS.
According to Dutch privacy legislation, data analysis was only
allowed to authorized researchers (KU, FBG) from designated in-
stitutions inside a secure environment after approval from the
institutional ethical committee. Furthermore, output was checked
by the CBS for privacy violations before it was allowed for publi-
cation purposes. Autopsywas not routinely performed. The cause of
death was deﬁned as the initial cause of health deterioration,
consequently resulting in death. This approach is similar to the
strategy used for the overall Dutch population. The causes of death
were grouped according to the International Classiﬁcation of Dis-
eases, 10th Revision (ICD-10). For cardiovascular death, the following
codes were used: I10-I79; for cancer-related death: C00-C43, C45-
C97, D00-D03, and D05e09; for death due to obstructive pulmo-
nary disease: J40-J47; and for digestive system-related causes: K00-
K93.
For survival estimation in the general population, a comparative
age and gender matched control group was derived from civil
registries of the Dutch population ealso maintained by the CBSe
for both the AAA and PAD group separately. To assess differences in
causes of death compared to the general population, deaths in the
respective study groups were individually matched on de-
mographic properties to cause of death distributions in the general
population. For example, if deaths in the AAA group consisted for
5% of males between the aged between 80 and 85 at the time of
death, the AAA matched cohort corresponds proportionally to the
death distribution for males with the same age and gender char-
acteristics from the general population.
2.4. Statistical methods
Baseline characteristics were described as counts and percent-
ages (dichotomous variables), or means and standard deviations
(continuous variables). Differences at baseline were determined
using Pearson's chi-square analysis and student t-test, where
appropriate. Survival for the aneurysmal and occlusive disease
cohorts was initially assessed using Kaplan-Meier and log-rank
analyses. Differences in the vital prognosis were subsequently
investigated using adjusted Cox proportional hazards regression.
Multivariable analyses adjusted for demographics, comorbidities,
and other risk factors (age, gender, diabetes mellitus, ischemic
heart disease [IHD], history of cancer, renal insufﬁciency, BMI, and
current smoking). The AAA group was designated as the reference
category in these analyses. Prognostic risk proﬁles for the two study
groups were established by determining hazard ratios for potential
risk factors separately for the AAA and PAD group using Cox pro-
portional hazards model. Univariately signiﬁcant covariates were
included in the multivariable model. All tests were two-sided and
signiﬁcance was considered when p-value < 0.05. Statistical anal-
ysis was performed using the SPSS Statistics 20 (IBM Inc., Chicago,
IL).
3. Results
A total of 470 patients undergoing elective surgery for AAA and
353 patients for PAD were identiﬁed. In the AAA group, 40 patients
were excluded because of prior treatment for PAD, while 14 pa-
tients were excluded in the PAD group for prior aneurysm treat-
ment. Two patients, one in each treatment group, were excluded
due to unavailable follow-up data as a result of emigration. The
remaining 429 AAA and 338 PAD patients were considered suited
for analysis.ospitalar Lisboa Central August 22, 2016.
. Copyright ©2016. Elsevier Inc. All rights reserved.
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Baseline characteristics are detailed in Table 1. Compared to the
PAD group, AAA patients were older at the time of surgery (71.7 vs.
63.3 years, p < 0.001), and more often male (88% vs. 66%, p < 0.001).
In addition, patients in the AAA group were more commonly
affected by cancer (21% vs. 14%, p ¼ 0.025) and renal insufﬁciency
(29% vs. 20%, p ¼ 0.006). Conversely, diabetes and current smoking
were less common among AAA patients (16% vs. 30%, p < 0.001 and
38% vs. 49%, p ¼ 0.003, respectively). AAA patients also less
frequently underwent vascular interventions prior to the index
operation (4% vs. 46%, p < 0.001).
3.2. Overall survival
During a median follow-up of 3.6 years after surgery (IQR:
2.1e5.4 years) 154 patients died in the AAA group. For PAD patients,
median follow-up time was 3.8 years (IQR: 2.0e5.9 years), during
which 107 patients died. Postoperative survival proved to be similar
for the two groups, in both unadjusted analysis, as determined by
log-rank testing (p ¼ 0.105; Fig. 1A), as well as adjusted Cox-
regression analysis (HR: 1.16, 95% CI: 0.87e1.54, Table 2). Howev-
er, since AAA patients were substantially older at the time of
intervention (71.7 vs. 63.3 years), postoperative survival did not
adequately reﬂect life expectancy of the respective groups. Fig. 1B
represents the postoperative life expectancies for the two groups
with the average age at the time of treatment as the starting point.
A direct comparison with a Dutch general population with similar
age and gender properties shows that in particular survival in the
PAD cohort more strongly deviates from its matched general pop-
ulation (30.0% vs.16.9%, respectively), indicatingmore life years lost
as compared to the AAA cohort.
3.3. Cause of death
Causes of death could be obtained for 153 out of 154 patients
(99.4%) in the AAA group and for all 107 deceased patients in the
PAD group. Deaths were classiﬁed in ﬁve categories: cardiovascular,
cancer-related, chronic obstructive pulmonary disease (COPD), in-
testinal disease, and other causes (Fig. 2). Cardiovascular mortality
was the leading cause of death in both AAA and PAD patients (35.3%
vs. 39.3%, p ¼ 0.944), followed by cancer-related death (28.8% vs.
24.3%, respectively, p ¼ 0.220). However, cardiovascular mortality
encompasses a much larger proportion in the PAD group as
compared to the age- and gender-matched general populationTable 1







Female gender e n (%) 51 (12) 114 (34) <0.001
Age e (years, mean ± SD) 71.7 ± 7.5 63.3 ± 11.1 <0.001
Cardiovascular risk factors
Diabetese n (%) 67 (16) 102 (30) <0.001
Hypertension e n (%) 291 (68) 231 (69) 0.782
Current smoking e n (%) 161 (38) 164 (49) 0.003
Body mass index e (mean ± SD) 26.2 ± 4.1 25.8 ± 4.6 0.217
Peripheral artery disease e n (%) 40 (9.3%) 338 (100%) e
Comorbidities
History of cancer e n (%) 88 (21) 48 (14) 0.025
Ischemic heart disease e n (%) 203 (47) 152 (45) 0.512
Coronary revascularization e n (%) 92 (21) 80 (24) 0.613
Cerebrovascular disease e n (%) 73 (17) 52 (15) 0.544
Renal insufﬁciency e n (%) 125 (29) 69 (20) 0.006
History of vascular interventions e n (%) 19 (4) 157 (46) <0.001
Fig. 1. Long-term survival analysis for postoperative survival after AAA and PAD.
(A) Kaplan-Meier analysis comparing survival after surgical intervention for AAA and
PAD. (B) Postoperative life expectancy for patients treated for AAA and PAD. The
starting points of the survival curves correspond to the average age at intervention in
the study groups (i.e. 63.3 and 71.7 years, respectively in the PAD and AAA groups).
Survival estimates of the general population are age- and gender-adjusted in accor-
dance with the respective cohorts.
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to intestinal disease or other causes was similar in the AAA and the
PAD group (5.9% vs. 1.9%, p ¼ 0.124; 21.6% vs. 31.8%, p ¼ 0.249,
respectively). Mortality resulting from COPD, however, was signif-
icantly more common among AAA patients compared to PAD pa-
tients (8.5 vs. 2.8%, p ¼ 0.043).
Risk adjusted survival analysis was additionally performed to
assess whether cause-speciﬁc mortality risks differed between AAApitalar Lisboa Central August 22, 2016.
pyright ©2016. Elsevier Inc. All rights reserved.
Table 2
Adjusted survival analysis for overall and cause-speciﬁc mortality. The AAA
group served as the reference category.
Univariate Multivariate
HR 95% CI HR 95% CI
Overall death 0.82 0.64e1.04 1.16 0.87e1.54
Cardiovascular death 0.91 0.61e1.37 1.47 0.93e2.31
Cancer-related death 0.70 0.43e1.14 1.14 0.64e2.03
Fig. 2. Cause of death distribution in the AAA and PAD groups and an age- and gender-
matched general Dutch population.
K.H.J. Ultee et al. / Atherosclerosis 252 (2016) 147e152150and PAD patients. These analyses showed that no difference exists
in risks of cardiovascular and cancer-related death between treat-
ment groups (HR: 1.47, 95% CI: 0.93e2.31; HR: 1.14, 95% CI:
0.64e2.03, respectively, Table 2). For causes of death with smaller
proportions, adjusted survival analysis was not possible due to
limited number of events.3.4. Risk proﬁle all-cause mortality
Risk proﬁle analysis was performed for the two study groups
separately (Table 3). In the AAA group, univariately signiﬁcant risk
factors that proved to be independently associated with increasedTable 3
Risk proﬁles for all-cause mortality for the AAA and PAD group.
Variables AAA
Univariate Multivariate
HR 95% CI HR 95
Age per 10 year incr. 1.83 1.47e2.30 1.70 1.
Gender 1.06 0.64e1.76 e e
Diabetes 0.91 0.58e1.45 e e
IHD 1.41 1.03e1.94 1.33 0.
Cancer 2.57 1.84e3.59 2.44 1.
Renal insufﬁciency 1.96 1.42e2.71 1.78 1.
Hypertension 1.39 0.98e1.97 e e
BMI per unit incr. 0.93 0.89e0.97 0.93 0.
Current smoking 0.90 0.65e1.25 e e
Downloaded from ClinicalKey.com at Centro H
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crease), history of cancer (HR: 2.44, 95% CI: 1.72e3.46) and renal
insufﬁciency (HR: 1.78, 95% CI: 1.27e2.51). Higher BMI was pro-
tective against mortality (HR: 0.93, 95% CI: 0.89e0.97, per BMI unit
increase). Ischemic heart disease appeared to negatively affect
survival of AAA patients in univariable analysis, but this effect was
lost in the multivariable model (HR: 1.33, 95% CI: 0.95e1.85).
Similar risk factors found in the PAD cohort were age (HR: 1.30,
95% CI: 1.08e1.57, per 10 year increase), a history of cancer (2.26,
95% CI: 1.45e3.54) and renal insufﬁciency (HR: 1.57, 95% CI:
1.02e2.42). Additionally, diabetes (HR: 1.69, 95% CI: 1.14e2.50) and
ischemic heart disease (HR: 1.76, 95% CI: 1.18e2.60) worsened
survival of PAD patients. Hypertensionwas a signiﬁcant predictor of
mortality in univariable analysis in the PAD group, but could not be
established as an independent risk factor in the adjusted model
(HR: 1.18, 95% CI: 0.75e1.85).4. Discussion
This study demonstrates that postoperative survival is similar
for patients undergoing surgery for aneurysmal or atherosclerotic
occlusive arterial disease, despite the fact that PAD patients were
almost 10 years younger at the time of surgery. Themortality rate of
PAD patients was much higher than that of AAA patients as
compared to their respective age- and gender-matched general
populations. These data indicate a relatively greater loss of life years
in PAD patients as compared to AAA patients.
What causes this difference in life expectancy between PAD and
AAA patients? The leading causes of death, i.e. cardiovascular dis-
ease and cancer, were similar in the two patient groups in unad-
justed as well as adjusted analyses. This is in agreement with a
study from the REACH registry, showing no difference in 1-year
cardiovascular death between the two patient groups [8]. Inter-
estingly, however, the proportion of cardiovascular mortality in
PAD patients was almost 50% higher than in the age- and gender-
matched general population, whereas in the AAA group the dif-
ference with the general populationwas rather small. This suggests
that cardiovascular disease is a relatively more important deter-
minant of life expectancy in PADwhen compared to AAA patients in
spite of their younger age. These ﬁndings are in line with previous
studies showing more severe systemic atherosclerosis e reﬂected
by increased carotid intima-media thickness e in patients with
occlusive arterial disease as compared to those with AAA [7,12e16].
Interestingly, it has been demonstrated that as little as a tenth of a
millimeter increase in arterial wall thickness is already associated
with considerable increases in risk of myocardial infarction, stroke,
and even death [24e27]. In PAD patients, a relatively severe pro-
gression of atherosclerotic disease is therefore likely to be
responsible for the similar survival compared to the much olderPAD
Univariate Multivariate
% CI HR 95% CI HR 95% CI
34e2.15 1.47 1.22e1.76 1.30 1.08e1.57
1.15 0.77e1.70 e e
2.03 1.38e2.99 1.69 1.14e2.50
95e1.85 2.01 1.36e2.96 1.76 1.18e2.60
72e3.46 3.14 2.04e4.82 2.26 1.45e3.54
27e2.51 2.46 1.64e3.69 1.57 1.02e2.42
1.62 1.04e2.52 1.18 0.75e1.85
89e0.97 1.03 0.98e1.07 e e
0.93 0.64e1.37 e e
ospitalar Lisboa Central August 22, 2016.
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general population. Of note, COPD-related deathwasmore frequent
among AAA patients, which may be due to a common -genetically
determined- defect in the extracellular matrix [28,29]. This further
supports the divergence in pathophysiology between aneurysmal
and occlusive vascular disease.
In order to identify what drives mortality in the respective
groups, we compared their mortality risk proﬁles. These analyses
showed that age was more than twice as important for AAA pa-
tients as compared to PAD patients (HR: 1.70 vs. 1.30, per 10 year
increase). Conversely, a history of ischemic heart disease and the
presence of diabetes were more important for the prediction of
death in PAD patients. Besides hazardous risk estimators, we found
that higher BMI was associated with prolonged survival in the AAA
group. This phenomenon, known as the obesity paradox, has been
described multiple times in many different study populations.
Although the exact mechanism for this phenomenon remains un-
known, the association between chronic disease and malnutrition
is believed to play a role [30,31]. The hazard ratios of 0.9 for current
smoking and diabetes in univariate analysis appear to represent a
protective effect of these factors for mortality. However, the wide
conﬁdence intervals indicate that rather no association existed
between these factors and mortality.
Since cardiovascular risk factors, as opposed to age, are poten-
tially modiﬁable, this provides the opportunity to improve life ex-
pectancy in PAD patients. Regrettably, in spite of widespread
guidelines for cardiovascular risk management and the undeniable
beneﬁts of secondary prevention, studies such as the REACH reg-
istry show that PAD patients do not achieve adequate risk factor
control as frequently as individuals with coronary or cerebrovas-
cular disease [32], despite comparable risks of future cardiovascular
events. Pande et al. found that only 27% of primary PAD patients
were on antiplatelet therapy, and a mere 19% received statins [33].
Thus, there is still a large gap between therapeutic goals and cur-
rent secondary preventive care for PAD patients [34,35]. Further-
more, tight control of blood pressure (i.e.  130e135 mmHg), as
opposed to relaxed control (i.e. 140 mmHg), is associated with a
further reduction in cardiovascular morbidity and mortality
[36,37]. The recent SPRINT trial even determined that blood pres-
sure control with a target of <120 mmHg resulted in a 43% reduc-
tion in cardiovascular mortality [38]. Similarly, tight regulation of
blood glucose and lipids has been reported to improve the overall
and cardiovascular prognosis [39e41]. In light of these beneﬁts,
narrowing of the tolerable margins of these classical cardiovascular
risk factors should be considered, particularly in PAD patients.
This study has limitations that should be addressed. First, this
study is of retrospective nature, which has inherent limitations
with regard to data collection. Also, it should be considered that
only patients who underwent surgery were identiﬁed. Patients
treated conservatively, or by less invasive -percutaneous- tech-
niques, and those with prohibitive surgical risks were not included
in this study. Although this approach provided more uniformity in
terms of severity of disease and operative risks, a selection bias
towards patients suited for surgery may have resulted. Also, Dutch
law prohibits the documentation of ethnicity in medical records,
which precluded its consideration in this study. For reference, a
review of the ethnical proportions in the Dutch general population
showed that 77.8% is of Dutch descent, 6.2% African descent, and
7.0%Mediterranean descent. In addition, it is virtually impossible to
determine the onset of aneurysmal or atherosclerotic disease. As
surgical treatment is a uniform indicator of severe disease, long-
term survival was assessed from the day of surgery onward. PAD
patients more often underwent some kind of revascularization
prior to the index operation in this study, which indicates that the
age difference demonstrated for timing of the index operationDownloaded from ClinicalKey.com at Centro Hos
For personal use only. No other uses without permission. Cobetween occlusive and aneurysmal disease may even underesti-
mate the difference in the age at onset between the two respective
diseases. This adds support to the argument that AAA and PAD are
two distinct entities. Finally, the increasing utilization of endovas-
cular treatment approaches warrants evaluation and comparative
assessment of the postoperative prognosis following minimally
invasive AAA and PAD treatment under local anesthesia.
In conclusion, this study shows that aneurysmal and occlusive
vascular disease do not only differ in terms of etiology and patho-
physiology, but are also distinct entities in terms of prognosis. Life
expectancy in PAD patients is shorter and is predominantly reduced
by cardiovascularmorbidity, as opposed to age in AAA patients. This
warrants emphasis on aggressive cardiovascular risk factor modi-
ﬁcation particularly for PAD patients in order to maximize
longevity.
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